320 related articles for article (PubMed ID: 9425933)
41. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
42. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy.
Gonzales E; Gerhardt MF; Fabre M; Setchell KD; Davit-Spraul A; Vincent I; Heubi JE; Bernard O; Jacquemin E
Gastroenterology; 2009 Oct; 137(4):1310-1320.e1-3. PubMed ID: 19622360
[TBL] [Abstract][Full Text] [Related]
43. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
[TBL] [Abstract][Full Text] [Related]
44. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children.
Vajro P; Franzese A; Valerio G; Iannucci MP; Aragione N
J Pediatr; 2000 Jun; 136(6):739-43. PubMed ID: 10839869
[TBL] [Abstract][Full Text] [Related]
45. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
46. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
[TBL] [Abstract][Full Text] [Related]
47. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
48. Analysis of bile acids and bile alcohols in urine by capillary column liquid chromatography-mass spectrometry using fast atom bombardment or electrospray ionization and collision-induced dissociation.
Yang Y; Griffiths WJ; Nazer H; Sjövall J
Biomed Chromatogr; 1997; 11(4):240-55. PubMed ID: 9257002
[TBL] [Abstract][Full Text] [Related]
49. [Bile acids in the therapy of chronic liver diseases].
Sperandeo M; Varriale A; Sperandeo G; Carughi S; Lucentini L
Recenti Prog Med; 1993 Mar; 84(3):225-30. PubMed ID: 8465104
[TBL] [Abstract][Full Text] [Related]
50. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.
Degott C; Zafrani ES; Callard P; Balkau B; Poupon RE; Poupon R
Hepatology; 1999 Apr; 29(4):1007-12. PubMed ID: 10094939
[TBL] [Abstract][Full Text] [Related]
51. Treatment of patients with chronic hepatitis using ursodeoxycholic acid.
Nambu M; Iijima T
Trop Gastroenterol; 1993; 14(2):59-65. PubMed ID: 8291125
[TBL] [Abstract][Full Text] [Related]
52. Hepatic morphology and bile acid composition of bile and urine during chenodeoxycholic acid therapy for radiolucent gallstones.
Pedersen L; Bremmelgaard A
Scand J Gastroenterol; 1976; 11(4):385-9. PubMed ID: 935799
[TBL] [Abstract][Full Text] [Related]
53. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006.
Nash KL; Allison ME; McKeon D; Lomas DJ; Haworth CS; Bilton D; Alexander GJ
J Cyst Fibros; 2008 May; 7(3):252-7. PubMed ID: 18042441
[TBL] [Abstract][Full Text] [Related]
54. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis.
Batta AK; Salen G; Mirchandani R; Tint GS; Shefer S; Batta M; Abroon J; O'Brien CB; Senior JR
Am J Gastroenterol; 1993 May; 88(5):691-700. PubMed ID: 8480734
[TBL] [Abstract][Full Text] [Related]
55. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
56. A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon.
Asciutti S; Castellani D; Nardi E; Morelli O; Clementi M; Chistolini F; Gentili G; Setchell KD; O'Connell N; Pellicciari R; Clerici C
Anticancer Res; 2009 Dec; 29(12):4971-9. PubMed ID: 20044604
[TBL] [Abstract][Full Text] [Related]
57. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
58. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
[TBL] [Abstract][Full Text] [Related]
59. Cystic fibrosis. Is treatment with ursodeoxycholic acid of value?
Strandvik B; Lindblad A
Scand J Gastroenterol Suppl; 1994; 204():65-7. PubMed ID: 7824881
[TBL] [Abstract][Full Text] [Related]
60. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
